Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Local Structures and Heterogeneity of Silica-Supported M(III) Sites Evidenced by EPR, IR, NMR, and Luminescence Spectroscopies.

Delley MF, Lapadula G, Núñez-Zarur F, Comas-Vives A, Kalendra V, Jeschke G, Baabe D, Walter MD, Rossini AJ, Lesage A, Emsley L, Maury O, Copéret C.

J Am Chem Soc. 2017 Jun 21. doi: 10.1021/jacs.7b02179. [Epub ahead of print]

PMID:
28582614
2.

Magnetic Memory from Site Isolated Dy(III) on Silica Materials.

Allouche F, Lapadula G, Siddiqi G, Lukens WW, Maury O, Le Guennic B, Pointillart F, Dreiser J, Mougel V, Cador O, Copéret C.

ACS Cent Sci. 2017 Mar 22;3(3):244-249. doi: 10.1021/acscentsci.7b00035. Epub 2017 Feb 22.

3.

Unexpected viral relapses in HCV-infected patients diagnosed with hepatocellular carcinoma during treatment with DAAs.

Soria A, Fabbiani M, Lapadula G, Gori A.

Hepatology. 2017 Mar 30. doi: 10.1002/hep.29181. [Epub ahead of print] No abstract available.

PMID:
28370176
4.

Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis.

Faverio P, Stainer A, Bonaiti G, Zucchetti SC, Simonetta E, Lapadula G, Marruchella A, Gori A, Blasi F, Codecasa L, Pesci A, Chalmers JD, Loebinger MR, Aliberti S.

Int J Mol Sci. 2016 Nov 16;17(11). pii: E1913.

5.

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.

Costarelli S, Cozzi-Lepri A, Lapadula G, Bonora S, Madeddu G, Maggiolo F, Antinori A, Galli M, Di Perri G, Viale P, d'Arminio Monforte A, Gori A; ICONA Foundation Study Group.

PLoS One. 2016 Oct 7;11(10):e0160761. doi: 10.1371/journal.pone.0160761. eCollection 2016.

6.

Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.

Lapadula G, Bernasconi DP, Casari S, Maggiolo F, Cauda R, Di Pietro M, Ladisa N, Sighinolfi L, Dal Zoppo S, Sabbatini F, Soria A, Pezzoli C, Mondi A, Costarelli S, Valsecchi MG, Torti C, Gori A; Italian MASTER cohort.

PLoS One. 2016 Sep 15;11(9):e0162320. doi: 10.1371/journal.pone.0162320. eCollection 2016.

7.

Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function.

Postorino MC, Quiros-Roldan E, Maggiolo F, Di Giambenedetto S, Ladisa N, Lapadula G, Lorenzotti S, Sighinolfi L, Castelnuovo F, Di Pietro M, Gotti D, Mazzini N, Torti C; MASTER Study Group.

Open AIDS J. 2016 Jul 15;10:136-43. doi: 10.2174/1874613601610010136. eCollection 2016.

8.

Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.

Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group.

J Antimicrob Chemother. 2016 Sep;71(9):2663-9. doi: 10.1093/jac/dkw185. Epub 2016 Jun 5.

PMID:
27272727
9.

The Nature of Secondary Interactions at Electrophilic Metal Sites of Molecular and Silica-Supported Organolutetium Complexes from Solid-State NMR Spectroscopy.

Conley MP, Lapadula G, Sanders K, Gajan D, Lesage A, del Rosal I, Maron L, Lukens WW, Copéret C, Andersen RA.

J Am Chem Soc. 2016 Mar 23;138(11):3831-43. doi: 10.1021/jacs.6b00071. Epub 2016 Mar 8.

PMID:
26887899
10.

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.

Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group.

PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015.

11.

Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).

Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, Gori A, Sighinolfi L, Pan A, Cauda R, Scalzini A, Quiros-Roldan E, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnuovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G.

Int J Epidemiol. 2017 Apr 1;46(2):e12. doi: 10.1093/ije/dyv192. No abstract available.

PMID:
26445966
12.

CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.

Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, Lichtner M, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group.

Lancet HIV. 2015 Mar;2(3):e98-106. doi: 10.1016/S2352-3018(15)00006-5. Epub 2015 Feb 6.

PMID:
26424550
13.

Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis.

Bonaiti G, Pesci A, Marruchella A, Lapadula G, Gori A, Aliberti S.

Biomed Res Int. 2015;2015:197950. doi: 10.1155/2015/197950. Epub 2015 May 27. Review.

14.

Corrigendum: Polymerization of Ethylene by Silica-Supported Dinuclear Cr(III) Sites through an Initiation Step Involving C-H Bond Activation.

Conley MP, Delley MF, Siddiqi G, Lapadula G, Norsic S, Monteil V, Safonova OV, Copéret C.

Angew Chem Int Ed Engl. 2015 Jun 1;54(23):6670. doi: 10.1002/anie.201503694. No abstract available.

PMID:
26055092
15.

Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART.

Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, Maggiolo F, Focà E, Ladisa N, Sighinolfi L, Di Pietro M, Pan A, Torti C; Italian MASTER Cohort.

PLoS One. 2015 May 28;10(5):e0124741. doi: 10.1371/journal.pone.0124741. eCollection 2015.

16.

Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study.

Raffetti E, Albini L, Gotti D, Segala D, Maggiolo F, di Filippo E, Saracino A, Ladisa N, Lapadula G, Fornabaio C, Castelnuovo F, Casari S, Fabbiani M, Pierotti P, Donato F, Quiros-Roldan E; MASTER Cohort.

BMC Public Health. 2015 Mar 12;15:235. doi: 10.1186/s12889-015-1565-0.

17.

Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.

Lapadula G, Gori A.

Ann Intern Med. 2015 Mar 17;162(6):461. doi: 10.7326/L15-5066-2. No abstract available.

PMID:
25775333
18.

Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients.

Lapadula G, Costarelli S, Chatenoud L, Castelli F, Astuti N, Di Giambenedetto S, Quiros-Roldan E, Sighinolfi L, Ladisa N, Di Pietro M, Zoncada A, Di Filippo E, Gori A, Nasta P, Torti C; Italian MASTER Cohort.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):312-8. doi: 10.1097/QAI.0000000000000585.

PMID:
25723139
19.

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice.

Costarelli S, Cozzi-Lepri A, Lapadula G, Bonora S, Madeddu G, Maggiolo F, Antinori A, Gori A, D'Arminio-Monforte A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19571. doi: 10.7448/IAS.17.4.19571. eCollection 2014.

20.

The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe.

Mocroft A, Ryom L, Lapadula G, Reiss P, Blaxhult A, Furrer H, Kutsyna G, Gatell J, Begovac J, Kirk O, Lundgren J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19561. doi: 10.7448/IAS.17.4.19561. eCollection 2014.

Supplemental Content

Loading ...
Support Center